Texas Tech University Health Sciences Center

ttuhsc.edu

Total trials

141

Active

23

Phase 3

5

Total enrollment

9,339

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cefadroxil 500 mg1
Clindamycin1
Bactrim DS1
linaclotide or placebo1
Ketamine1
standard general anesthesia1
sulforaphane2
DeltaGold® Tocotrienol 70%2
Cryoablation combined with PD1 Inhibitor1
Pecan snack1
Pretzel snack1
Low curcumin group1
High curcumin group1
Dexamethasone1
Zynrelef1
Exparel1

Next readouts

  • 2024-12-30
  • 2025-08-30
  • 2025-11-01
  • 2025-11-01
  • 2026-10
  • 2026-12-31
  • 2027-01
  • 2027-05
  • 2027-12-30
  • 2027-12-31

Top conditions

  • Obesity10
  • Breast Cancer7
  • Low Back Pain5
  • Burns4
  • Tuberculosis3
  • Respiratory Failure3
  • Acute Respiratory Distress Syndrome2
  • Pharmacokinetics2

Frequently asked questions about Texas Tech University Health Sciences Center

How many clinical trials does Texas Tech University Health Sciences Center have on ClinicalTrials.gov?
Texas Tech University Health Sciences Center is listed as the lead sponsor on 141 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
How many of Texas Tech University Health Sciences Center's trials are in Phase 3?
5 of Texas Tech University Health Sciences Center's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Texas Tech University Health Sciences Center focus on?
Texas Tech University Health Sciences Center's most-studied conditions on ClinicalTrials.gov are Obesity, Breast Cancer, Low Back Pain, Burns, Tuberculosis.
When are Texas Tech University Health Sciences Center's next clinical trial readouts?
Texas Tech University Health Sciences Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Tocotrienols for Obesity of Postmenopausal Women”, expected around 2024-12-30.